Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients – results from real-life prospective study.

Autor:	Horňák, Tomáš, Semerád, Lukáš, Žáčková, Daniela, Weinbergerová, Barbora, Šustková, Zuzana, Procházková, Jiřina, Bělohlávková, Petra, Stejskal, Lukáš, Rohoň, Peter, Faber, Edgar, Žák, Pavel, Mayer, Jiří, Ráčil, Zdeněk
Předmět:	BLOOD serum analysis STATINS (Cardiovascular agents) CHRONIC myeloid leukemia PROTEIN-tyrosine kinase inhibitors IMATINIB CARDIOVASCULAR diseases risk factors BLOOD lipid measurement
Zdroj:	Leukemia & Lymphoma; Feb2020, Vol. 61 Issue 2, p494-496, 3p
Abstrakt:	There were significantly more patients already on or newly indicated for statins at the start of IMA treatment (68% - 7/34 and 16/34 patients, respectively) compared to NILO (30% - 3/23 and 4/23 patients, respectively) ( I p i =.0076). During the first year of IMA therapy, 2/34 (6%) patients with a previous low CV risk moved to a high/very high-risk category and 2/11 IMA patients not indicated for or using statins from start fulfilled the criteria for statin therapy, which was then initiated. Although NILO and IMA induce fast alterations in lipid metabolism, we found that these abnormalities do not cause changes in CV risk or induce the need for statin therapy during the first year of TKI treatment. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.